650 related articles for article (PubMed ID: 26491259)
21. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
[TBL] [Abstract][Full Text] [Related]
22. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
23. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of crizotinib in NSCLC patients.
Hamilton G; Rath B; Burghuber O
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):835-42. PubMed ID: 25732197
[TBL] [Abstract][Full Text] [Related]
25. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
Dikopf A; Wood K; Salgia R
Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
[TBL] [Abstract][Full Text] [Related]
26. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
Yi ES; Chung JH; Kulig K; Kerr KM
Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
[TBL] [Abstract][Full Text] [Related]
27. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
28. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Arbour KC; Riely GJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
[TBL] [Abstract][Full Text] [Related]
30. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R
Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949
[TBL] [Abstract][Full Text] [Related]
31. [Clinical Efficacy of Crizotinib in Advanced ALK Positive
Non-small Cell Lung Cancer].
Zhao J; Zhang K; Zhang L; Wang H
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
33. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.
Lu S; Zhang J; Ye M; Wang B; Wu B
Pharmacogenomics; 2016 Jun; 17(9):985-94. PubMed ID: 27266545
[TBL] [Abstract][Full Text] [Related]
34. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
J Clin Oncol; 2016 Oct; 34(28):3383-9. PubMed ID: 27354483
[TBL] [Abstract][Full Text] [Related]
35. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
[TBL] [Abstract][Full Text] [Related]
36. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016
[TBL] [Abstract][Full Text] [Related]
37. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
Lee JA; Bubendorf L; Stahel R; Peters S
Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
[TBL] [Abstract][Full Text] [Related]
38. ALK in lung cancer: past, present, and future.
Shaw AT; Engelman JA
J Clin Oncol; 2013 Mar; 31(8):1105-11. PubMed ID: 23401436
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib resistance: implications for therapeutic strategies.
Dagogo-Jack I; Shaw AT
Ann Oncol; 2016 Sep; 27 Suppl 3(Suppl 3):iii42-iii50. PubMed ID: 27573756
[TBL] [Abstract][Full Text] [Related]
40. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
